HONG KONG – South Korean biopharma Genesen Inc. has secured ₩2.2 billion (US$1.9 million) in seed funding to advance its peptide-based drug candidates for the treatment of autoimmune and inflammatory diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis and psoriasis.
HONG KONG – South Korean biopharma Genesen Inc. has secured ₩2.2 billion (US$1.9 million) in seed funding to advance its peptide-based drug candidates for the treatment of autoimmune and inflammatory diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis and psoriasis.
DUBLIN – Imcheck Therapeutics SAS raised €48 million (US$53.2 million) in a series B financing round to move a pipeline of antibodies targeting gamma delta T cells into the clinic.
Pandion Therapeutics Inc.'s deal with Astellas Pharma Inc. brings as much as $45 million in up-front money and payments related to research and preclinical activities, with potentially more than $750 million in development and commercial milestone rewards to come, plus royalties if products reach the market.
LONDON – Mirobio Ltd. has spun out of Oxford University, raising £27 million (US$33.3 million) to develop antibody-based therapies designed to activate immune checkpoint receptors in the treatment of autoimmune disorders.
